Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
The post Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing appeared first on Above the Law.
from Above the Law https://ift.tt/t6QWmF3
via IFTTT